Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
Gujarat Kidney And Super Speciality Ltd (GKSL)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544666 NSE: GKSL Hospital & Healthcare Services | Small Cap | Guj. Kidney & Super Share Price
₹173.95 -4.15 (-2.33%)
As on 28-Sep'26 16:59
Gujarat Kidney And Super Speciality Ltd (GKSL)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 544666 NSE: GKSL Hospital & Healthcare Services | Small Cap | Guj. Kidney & Super Share Price
₹173.95 -4.15 (-2.33%)
As on 28-Sep'26 16:59
Key Metrics
Valuation Multiples
Market Cap
₹1,371 Cr.
Current Price
₹174
52-Week Low / High
₹98 / 187
TTM EPS
₹2
TTM Sales
₹101 Cr.
Book Value per Share
₹32.7
P/E Ratio
86.61
Lower than its 5-year historical median
Industry PE
98.6
Price to Book (P/B)
5.32
Price to Sales (P/S)
13.57
Lower than its 5-year historical median
EV/EBITDA
47.12
Lower than its 5-year historical median
Dividend Yield
0%
Profitability Efficiency
Return on Equity (ROE)
12.08%
Return on Capital Employed (ROCE)
15.51%
Return on Assets (ROA)
9.61%
Operating Profit Margin
32.9%
Net Profit Margin
20.5%
Gross Profit Margin
31.6%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
-
14.02%
Operating Profit Growth (1 Year)
-
62.78%
Net Profit Growth (1 Year)
-
76.95%
Asset Quality
Promoter Holding
71.45%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹242 Cr.
Equity
₹15.8 Cr.
Face Value
₹2
All Time Low / High
₹98.25 / 186.85
Check Before You Invest
Quality
Somewhat GoodValuation
Somewhat UndervaluedCheck Valuation charts
Price Trend
Strong
Is Gujarat Kidney And Super Speciality Ltd a good quality company?
Gujarat Kidney And Super Speciality Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does Gujarat Kidney And Super Speciality Ltd performance compare with that of its Peers?
Revenue growth of Gujarat Kidney And Super Speciality Ltd vs industry peers?
Gujarat Kidney And Super Speciality Ltd revenue CAGR is 0.00%, compared to the industry median CAGR of 0%, indicating stable growth and maintaining its market share.
Promoter shareholding and pledge status of Gujarat Kidney And Super Speciality Ltd?
Promoters hold 71.45% of the Gujarat Kidney And Super Speciality Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of Gujarat Kidney And Super Speciality Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Gujarat Kidney And Super Speciality Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|
| ROCE % ⓘ | 38.4% | -1.7% | 30% | 62.6% | 9.6% | - |
| Value Creation Index ⓘ | 1.7 | -1.1 | 1.1 | 3.5 | -0.3 | - |
Growth Parameters ⓘ |
||||||
| Sales ⓘ | 0.8 | 0 | 5 | 35.2 | 40.1 | 38 |
| Sales YoY Gr. | - | -100% | NA | 606.2% | 14% | - |
| Adj EPS ⓘ | 0 | -0 | 0.3 | 1.6 | 1.3 | 1 |
| YoY Gr. | - | -100% | NA | 471.4% | -21.9% | - |
| BVPS (₹) ⓘ | 0.1 | 0.1 | 0.5 | 4.5 | 31.3 | 31.5 |
| Adj Net Profit ⓘ | 0.1 | -0 | 1 | 9.1 | 9.9 | 8 |
| Cash Flow from Ops. ⓘ | 0 | 0 | -2.1 | 15.4 | -7.5 | - |
| Debt/CF from Ops. ⓘ | 0 | 0 | -0.9 | 0.1 | -1.7 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | NA | NA | NA | 14% | ||||
| Adj EPS ⓘ | NA | NA | NA | -21.9% | ||||
| BVPSⓘ | NA | NA | 557.5% | 599.3% | ||||
| Share Price | - | - | - | - | ||||
Key Financial Parameters ⓘ
| Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 25.9 | -1.6 | 17.1 | 50.2 | 7.3 | 3.3 |
| Op. Profit Mgn % ⓘ | 91.3 | 0 | 31.4 | 43.9 | 40.3 | 33.8 |
| Net Profit Mgn % ⓘ | 12.5 | 0 | 19.3 | 25.9 | 24.7 | 21.2 |
| Debt to Equity ⓘ | 0 | 0 | 1.1 | 0.1 | 0.1 | - |
| Working Cap Days ⓘ | 0 | 0 | 255 | 117 | 448 | 262 |
| Cash Conv. Cycle ⓘ | 0 | 0 | -268 | 41 | 112 | 151 |
Valuation of Guj. Kidney & Super - Consolidated
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|
| Sales | 0 | 0 | 5 | 40 | 82 |
| Operating Expenses ⓘ + | 0 | 0 | 3 | 24 | 55 |
| Operating Profit ⓘ | -0 | -0 | 2 | 17 | 27 |
| Operating Profit Margin (%) | - | - | 40.9% | 41.1% | 32.8% |
| Other Income ⓘ + | 1 | 0 | 1 | 0 | 1 |
| Interest ⓘ | 0 | 0 | 0 | 1 | 2 |
| Depreciation ⓘ | 1 | 0 | 0 | 3 | 5 |
| Profit Before Tax ⓘ | 0 | -0 | 2 | 13 | 21 |
| Tax ⓘ | 0 | 0 | 1 | 3 | 4 |
| Profit After Tax | 0 | -0 | 2 | 9 | 17 |
| PAT Margin (%) | - | - | 35.9% | 23.6% | 20.5% |
| Adjusted EPS (₹) | 0.0 | 0.0 | 0.5 | 1.7 | 2.0 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 0 | 0 | 2 | 26 | 253 | ||||||
| Debt + | 0 | 0 | 2 | 3 | 15 | ||||||
| Minority Interest | 0 | 0 | 0 | 1 | 2 | ||||||
| Trade Payables | 3 | 3 | 2 | 3 | 8 | ||||||
| Others Liabilities ⓘ | -0 | -0 | 15 | 21 | 17 | ||||||
| Total Liabilities ⓘ | 4 | 4 | 20 | 55 | 295 | ||||||
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 3 | 0 | 14 | 31 | 129 | ||||||
| CWIP ⓘ | 0 | 0 | 0 | 0 | 0 | ||||||
| Investments ⓘ | 0 | 0 | 0 | 0 | 12 | ||||||
| Inventories | 0 | 0 | 0 | 1 | 2 | ||||||
| Trade Receivables | 1 | 1 | 4 | 15 | 39 | ||||||
| Cash Equivalents | 0 | 0 | 1 | 3 | 56 | ||||||
| Others Assets ⓘ | -0 | 3 | 1 | 5 | 58 | ||||||
| Total Assets ⓘ | 4 | 4 | 20 | 55 | 295 | ||||||
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 0 | 0 | 1 | 14 | -4 |
| Cash Flow From Investing Activity ⓘ + | 0 | 0 | 0 | -18 | -214 |
| Cash Flow From Financing Activity ⓘ + | 0 | 0 | -0 | 6 | 228 |
| Net Cash Flow ⓘ | 0 | 0 | 1 | 2 | 11 |
| PARTICULARS | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | N/A | N/A | 162.4 | 68.65 | 12.08 | |||||
| ROCE (%) | N/A | N/A | 35.61 | 63.02 | 15.51 | |||||
| Asset Turnover Ratio | 0 | 0 | 0.39 | 1.07 | 0.47 | |||||
| PAT to CFO Conversion(x) | N/A | N/A | 0.5 | 1.56 | -0.24 | |||||
| Working Capital Days | ||||||||||
| Receivable Days | 0 | 0 | 204.60 | 87.80 | 119.70 | |||||
| Inventory Days | 0 | 0 | 20.60 | 4.30 | 6.10 | |||||
| Payable Days | 0 | 0 | 3,365.80 | 250.60 | 234.30 | |||||
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
Gujarat Kidney And Super Speciality Ltd FAQs
The current trading price of Guj. Kidney & Super on 28-Sep-2026 16:59 is ₹173.9.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 27-Sep-2026 the market cap of Guj. Kidney & Super stood at ₹1,371.5 Cr
The latest P/E ratio of Guj. Kidney & Super as of 27-Sep-2026 is 170.6.
The latest P/B ratio of Guj. Kidney & Super as of 27-Sep-2026 is 5.52.
The 52-week high of Guj. Kidney & Super is ₹186.8 and the 52-week low is ₹98.25.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Guj. Kidney & Super is ₹37.89 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that Gujarat Kidney And Super Speciality Ltd is a average quality company.
The key valuation ratios of Gujarat Kidney And Super Speciality Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Gujarat Kidney And Super Speciality Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About Gujarat Kidney And Super Speciality Ltd
Gujarat Kidney and Super Speciality was incorporated under the name and style of ‘Vihaan Medicare Private Limited’, a private limited company on December 20, 2019. Subsequently, in order to align its name with the business carried out by the company of offering multi-speciality and super-speciality medical services, pursuant to a resolution passed by the board of directors in their meeting held on September 04, 2023, and by the shareholders in an extraordinary general meeting held on September 06, 2023, the name of the company was changed to ‘Gujarat Kidney and Super Speciality Private Limited’ on September 13, 2023. Further, the company was converted into a public limited company pursuant to a resolution passed by the board of directors in their meeting held on November 02, 2023 and by the Shareholders in an extraordinary general meeting held on November 04, 2023 and consequently the name of the company was changed to ‘Gujarat Kidney and Super Speciality Limited’.
The company operates a chain of mid-sized multi-speciality hospitals, providing integrated healthcare services, with a focus on secondary (which are surgical services) and tertiary care (which are super speciality surgical services). Its hospitals provide integrated diagnostic services, either in-house, and pharmacies that cater to its patients. It endeavours to provide quality and affordable healthcare services to all its patients. The company wholly owns some of the hospitals but manage the operations of each of the hospitals through a separate professional management team. Each of its hospitals is managed by a Chief Operating Officer, who is responsible for supervising day to day functioning. This structure provides the company with greater control over its hospitals and helps it to deliver quality healthcare services.
The company is led by Pragnesh Yashwantsingh Bharpoda, who has vast experience in the medical industry. He has helped the company expand its geographical presence by strategically acquiring various multi-speciality hospitals, over the years.
Business area of the company
The company, along with its subsidiaries, is a multi-specialty healthcare institution and is engaged in providing comprehensive medical services, including inpatient and outpatient care, surgical procedures, diagnostic services, and emergency care.
Services of the company
Specialities services
- General Medicine
- General Surgery
- Laparoscopic Surgery
- Metabolic and Obesity Surgery
- IVF
- Obstetric and Gynaecology (OBGY)
- Ortho
- Joint Replacement
- Arthroscopy
- Endocrinology
- Diabetology
- Pulmonology
- Intensivist
- Skin and VD
- Radiology
- Pathology
- Psychiatrist
- Paediatric
- Ophthalmology
- ENT
- Physiotherapy
- Dietician
Super Specialities services
- Urology
- Cardiology
- Nephrology
- Neurology
- Neuro Surgery
- Oncology
- Onco Surgery
- Renal Transplant
- Vascular Surgery
- Gastroenterology
- Gastro Surgery
- Plastic Surgery
- Paediatric Surgery
- Hematology
- Spine Surgery
Awards, accreditations and recognition
- 2022: Registration of Gujarat Kidney Hospital with the Kidney Transplant Center under the Human Organs Transplantation Act, 1994.
- 2023: Renewal of registration of Gujarat Kidney Hospital with Kidney Transplant Center under the Human Organs Transplantation Act, 1994.
- 2023: Accreditation for its Gujarat Kidney Hospital by the National Accreditation Board for Hospital & Healthcare Provide.
History and milestones
- 2014: Established and commenced operations of its first hospital under the name of ‘Gujarat Kidney Hospital’ at Vadodara, Gujarat.
- 2018: Shifted Gujarat Kidney Hospital to a larger premises in Vadodara, Gujarat to expand the bed capacity from fifteen to sixty-five.
- 2018: Established five sub-specialities in its uro department, viz., endourology, urologic oncology, paediatric urology, reconstructive urology, and laparoscopic urology at its Gujarat Kidney Hospital.
- 2019: Set up an in-house interventional cardiology department under the name of ‘Gujarat Heart Care Unit’ for offering invasive cardiology services.
- 2021: Successfully carried out its first laparoscopic radical prostatectomy at its Gujarat Kidney Hospital.
- 2023: Established and commenced operations of its second hospital in Godhra, Gujarat.
- 2023: Successfully carried out its first renal transplant at its Gujarat Kidney Hospital.
- 2023: Successfully carried out its first Angiography at its Godhra Hospital.
- 2023: Established three in-house super-speciality departments for cardiology, urology and nephrology at its Godhra Hospital.
- 2024: Successfully carried out its first retrograde intrarenal surgery (RIRS) at its Godhra Hospital.
- 2024: Acquired majority stake in Raj Palmland Hospital Private Limited, thereby making it the company’s Subsidiary.
- 2024: Acquired the Gujarat Kidney Hospital.
- 2024: Acquired the Godhra Hospital.
- 2024: Acquired controlling interest of 90% in M/s Surya Hospital and ICU.
- 2024: Acquired controlling interest of 90% in M/s. Gujarat Surgical Hospital.
- 2025: Acquired Ashwini Medical Centre.
- 2025: Acquired Ashwini Medical Store.
- 2025: Acquired 51% of equity shares of Harmony Medicare Private Limited.
You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
